LONDON: GlaxoSmithKline's drug sales in China slumped 61 percent in the third quarter, hit by a bribery scandal that has damaged its ability to market products in the country and pushed some sales into the hands of rivals.
Chief Executive Andrew Witty said GSK's business in China had suffered most where other drug options were available - as is the case with its top-selling lung medicine Advair, for which AstraZeneca's Symbicort is an alternative treatment.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
